cause fatal hemorrhagic fevers. Hence Ebola and Marburg viruses are significant Biodefense threats, urrently there are no approved anti-viral agents or vaccines to combat these devastating pathogens. Recent successes in the HIV system support the concept of inhibiting enveloped virus entry by blocking either virus binding to or fusion with host cells. The long-term objective of this project is to develop small molecule inhibitors and/or therapeutic antibodies that block binding or fusion of Ebola and Marburg viruses with host cells. Our work to date supports the following model for Ebola virus entry. After binding to an as yet unidentified receptor(s), Ebola is endocytosed and delivered to the endosomal system. There, cathepsins B and L cleave the receptor binding subunit (GP1) of the single Ebola virus glycoprotein (GP) to a 19kDa intermediate that confers considerably enhanced binding and infection;19kDa GP1 thus defines a receptorbinding domain (RBD) of the Ebola virus GP. A final cathepsin L dependent activity triggers fusion and hence virus entry into the cell cytoplasm. The major goal of this proposal is to explore blockade of Ebola and Marburg virus binding to host cells as a means to prevent infection and therefore to ameliorate disease sequelae. To attain this goal, we will address the following specific aims: (1) identify the host cell receptor(s) for Ebola and Marburg viruses; (2) pan for and characterize mAbs that bind to the Ebola and Marburg virus RBDs;and (3) develop and employ a high throughput screen for small molecules that block receptor binding. The project will involve state of the art genomic, proteomic, molecular virology, and high throughput screening approaches. The project has a very high degree of health relatedness. Given the extremely high morbidity and mortality rates of filovirus infections, there is a pressing need for a collection of agents to combat filovirus infections in both pre- and post exposure situations, for example for health care, animal care, and laboratory research workers as well as for local populations at large during an outbreak.

Public Health Relevance

Ebola and Marburg viruses are category A priority pathogens that incur exceedingly high morbidity and mortality rates and for which there are no approved vaccines or anti-viral agents. The goal of this project is to develop therapeutics that target the earliest stages of Ebola and Marburg virus infections.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Maryland Baltimore
United States
Zip Code
Champion, Anna E; Bandara, Aloka B; Mohapatra, Nrusingh et al. (2018) Further Characterization of the Capsule-Like Complex (CLC) Produced by Francisella tularensis Subspecies tularensis: Protective Efficacy and Similarity to Outer Membrane Vesicles. Front Cell Infect Microbiol 8:182
Bridge, Dacie R; Blum, Faith C; Jang, Sungil et al. (2017) Creation and Initial Characterization of Isogenic Helicobacter pylori CagA EPIYA Variants Reveals Differential Activation of Host Cell Signaling Pathways. Sci Rep 7:11057
Kaempfer, Raymond; Popugailo, Andrey; Levy, Revital et al. (2017) Bacterial superantigen toxins induce a lethal cytokine storm by enhancing B7-2/CD28 costimulatory receptor engagement, a critical immune checkpoint. Receptors Clin Investig 4:
Molleston, Jerome M; Cherry, Sara (2017) Attacked from All Sides: RNA Decay in Antiviral Defense. Viruses 9:
Cifuentes-Muñoz, Nicolás; Sun, Weina; Ray, Greeshma et al. (2017) Mutations in the Transmembrane Domain and Cytoplasmic Tail of Hendra Virus Fusion Protein Disrupt Virus-Like-Particle Assembly. J Virol 91:
Sarute, Nicolás; Ross, Susan R (2017) New World Arenavirus Biology. Annu Rev Virol 4:141-158
Ramachandran, Girish; Aheto, Komi; Shirtliff, Mark E et al. (2016) Poor biofilm-forming ability and long-term survival of invasive Salmonella Typhimurium ST313. Pathog Dis 74:
Wahid, Rezwanul; Fresnay, Stephanie; Levine, Myron M et al. (2016) Cross-reactive multifunctional CD4+ T cell responses against Salmonella enterica serovars Typhi, Paratyphi A and Paratyphi B in humans following immunization with live oral typhoid vaccine Ty21a. Clin Immunol 173:87-95
Li, Huiguang; Hwang, Young; Perry, Kay et al. (2016) Structure and Metal Binding Properties of a Poxvirus Resolvase. J Biol Chem 291:11094-104
Chou, Yi-Ying; Cuevas, Christian; Carocci, Margot et al. (2016) Identification and Characterization of a Novel Broad-Spectrum Virus Entry Inhibitor. J Virol 90:4494-4510

Showing the most recent 10 out of 375 publications